FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI
In Brief: Recompetition Of Frederick Contract Flops, As Others Leave The Field To Litton-Bionetics
Search Committee Finishes Job, Submits Choices To Califano
New ACS Grants to Fund ‘Critical, Urgent’ Research
Sacharin Issue Splits Scientists; ACS Proposes Delaney Changes
UICC Announces Grant Programs to Continue
NCI Goofs On Contract Notice, Won’t Change Improper Deadline
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed
